Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis

Herpes Labialis Clinical Trial

— Squarex  

Official title:

A Clinical Trial to Test the Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01971385
• Other study ID #: 2013P001028
• Status: Completed
• Phase: Phase 1
• First received: October 17, 2013
• Last updated: May 5, 2017
• Start date: October 2013
• Est. completion date: September 2015

Study information

• Verified date: May 2017
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Subjects with a history of recurrent herpes labialis will be sensitized with either 2% SADBE or placebo. Following this, subjects sensitized with 2% SADBE will received.2% sqauric acid or.5% squaric acid on their cold sore within 72 hours of a recurrence. Subjects sensitized with placebo solution will receive placebo solution on their cold sore within 72 hours of a recurrence. Subjects will be followed for up to 6 mos after application of study medication.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: September 2015
• Est. primary completion date: September 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age >18

• With clinical diagnosis of herpes labialis.

• who self report having six or more episodes of herpes labialis in the previous 12 months.

Exclusion Criteria:

• Pregnant or lactating females.

• Current or recurrent infection or any underlying condition that may predispose to infection or anyone who has been admitted to the hospital due to bacteremia, pneumonia or any other serious infection.

• Therapy with glucocorticoid or immunosuppressant at time of recruitment or within past 4 weeks, except for inhaled corticosteroids for asthma.

• History of malignancy (except patients with surgically cured basal cell or squamous cell skin cancers who will be eligible)

• History of organ transplantation

• Negative HIV-positive status determined by history at screening or known history of any other immuno-suppressing disease.

• Severe comorbidities (diabetes mellitus requiring insulin, CHF (EF<50% at baseline will be exclusionary) of any severity, MI, CVA or TIA within 3 months of screening visit, unstable angina pectoris, oxygen-dependent severe pulmonary disease

• Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit.

• Subjects who have known hypersensitivity to Squaric acid or any of its components.

• History of recent alcohol or substance abuse (< 1 year)

• Any condition judged by the investigator to cause this clinical trial to be detrimental to the patient.

• History of psychiatric disease that would interfere with the patient's ability to comply with the study protocol

• History of non-compliance with other therapies.

Related Conditions & MeSH terms

• Herpes Labialis

Intervention

Drug:
• Squaric Acid solution

• Placebo solution

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Subjects With at Least One Form of Contact With Study Staff With no Herpes Labialis Outbreaks Within 119 Days of Sensitization	Percent of subjects with no reported herpes labialis outbreak within 119 days of sensitization over total number of subjects after one form of contact with study staff	8 months
Secondary	Number of Adverse Events Reported	To assess the safety and tolerability of squaric acid solution the number of adverse events in each treatment arm will be collected and compared.	8 months